Winway Health Desk
How payment integrity tools can help payers to tackle fraud, waste...
The United States spends an average of $3.8 trillion per year on healthcare. Some estimate that fraud, waste and abuse (FWA) costs the nation...
Less selling, more science can best help doctors navigate complex new...
The future of cancer drug marketing will be about helping oncologists understand the complexities of precision medicine and how new advances in targeted therapies...
Pfizer’s growth hormone deficiency drug comes up short at the FDA
A Pfizer biologic drug developed to offer more convenient dosing for children with growth hormone deficiency has been turned down by the FDA.
Pfizer...
Some states still pushing ineffective Covid antibody treatments
As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that...
Maximizing technology’s value with nursing informatics
The pandemic-driven technology revolution has transformed the healthcare industry more in the past two years than any other period in history. While some changes...
Virtual PT app is effective and now reimbursable
New research out of the Mayo Clinic published in Archives of Rehabilitation Research and Clinical Translation found that the Limber Health digital exercise therapy...
GlaxoSmithKline rushes to accelerate COVID-19 antibody output amid omicron-driven demand
GlaxoSmithKline and Vir Biotechnology are rushing to speed up production of their COVID-19 therapy, now that they're the only companies with an antibody that...
Doceree offers glimpse into trends of ‘programmatic marketing’
When HCPs' doors closed due to COVID-19, pharma opened a digital window.
A new study (PDF), "Programmatic Trends in Pharma HCP Marketing 2022" by Doceree,...
Kura Oncology leukemia clinical trial to resume after FDA lifts partial...
A Kura Oncology clinical trial that was paused in November after a patient death is now cleared to resume testing a drug for acute...
Fierce JPM Week: Bristol Myers’ next-gen autoimmune med not just another JAK...
After a high-profile study turned up safety risks for Pfizer's JAK inhibitor Xeljanz last year, the FDA put the entire class under a microscope—and...
